Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report) CEO Stephen R. Brady purchased 35,000 shares of Tempest Therapeutics stock in a transaction that occurred on Wednesday, July 3rd. The stock was acquired at an average price of $2.11 per share, with a total value of $73,850.00. Following the transaction, the chief executive officer now owns 46,376 shares in the company, valued at $97,853.36. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Tempest Therapeutics Stock Performance
Shares of TPST stock opened at $2.15 on Thursday. The company has a current ratio of 3.13, a quick ratio of 3.13 and a debt-to-equity ratio of 0.20. The stock has a 50 day simple moving average of $2.92 and a 200-day simple moving average of $3.55. The company has a market cap of $47.77 million, a price-to-earnings ratio of -1.25 and a beta of -1.73. Tempest Therapeutics, Inc. has a 12-month low of $0.17 and a 12-month high of $9.77.
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.08. On average, equities analysts forecast that Tempest Therapeutics, Inc. will post -1.57 EPS for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on TPST
Institutional Trading of Tempest Therapeutics
An institutional investor recently raised its position in Tempest Therapeutics stock. Virtu Financial LLC grew its stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) by 69.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,574 shares of the company’s stock after acquiring an additional 11,689 shares during the period. Virtu Financial LLC owned about 0.13% of Tempest Therapeutics worth $112,000 at the end of the most recent reporting period. Institutional investors own 22.52% of the company’s stock.
Tempest Therapeutics Company Profile
Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.
Recommended Stories
- Five stocks we like better than Tempest Therapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- This Stock’s Price Shifts Into High Gear With Analyst Upgrades
- The How And Why of Investing in Oil Stocks
- AI Boosts Glass Tech Leader Stock: Shares Up 75% and More to Come
- Airline Stocks – Top Airline Stocks to Buy Now
- AI Partnership Boosts This Top Tech Stock: Ready for More Gains?
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.